Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

48.88 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 48.88
Bid (Size) 46.00 (1)
Ask (Size) 52.03 (1)
Prev. Close 48.88
Today's Range 48.88 - 48.88
52wk Range 21.72 - 51.86
Shares Outstanding 160,500,999
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
BRIDGEBIO PHARMA INC (NASDAQ:BBIO) Shows Strong Technical Breakout Potential with High Momentum and Consolidation Setup
BridgeBio Pharma (BBIO) shows strong breakout potential with a perfect Technical Rating of 10 and Setup Rating of 9, signaling robust momentum and consolidation. Ideal for traders eyeing... 
Via Chartmill

Performance

YTD
+73.3%
+73.3%
1 Month
+6.5%
+6.5%
3 Month
+48.8%
+48.8%
6 Month
+34.7%
+34.7%
1 Year
+90.5%
+90.5%

More News

Read More
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics
From Helix Acquisition Corp. II
Via GlobeNewswire
Earnings Scheduled For August 5, 2025
Via Benzinga
BridgeBio Pharma Inc (NASDAQ:BBIO) Shares Drop 11% After Q2 2025 Earnings Miss Despite Revenue Beat
Via Chartmill
Topics Earnings
BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates
From BridgeBio Pharma, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET
From BridgeBio Pharma, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Is Pfizer Stock a Yield Trap?
Via The Motley Fool
Topics Intellectual Property
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
Via The Motley Fool
Topics Intellectual Property Retirement
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
The Smart Money Is Buying These 10 Stocks
Via Benzinga
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk
Via Benzinga
Topics World Trade
BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations
Via Investor's Business Daily
BridgeBio Reports First Quarter 2025 Financial Results and Business Updates
From BridgeBio Pharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is BridgeBio Pharma, Inc. - Common Stock publicly traded?
Yes, BridgeBio Pharma, Inc. - Common Stock is publicly traded.
What exchange does BridgeBio Pharma, Inc. - Common Stock trade on?
BridgeBio Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BridgeBio Pharma, Inc. - Common Stock?
The ticker symbol for BridgeBio Pharma, Inc. - Common Stock is BBIO on the Nasdaq Stock Market
What is the current price of BridgeBio Pharma, Inc. - Common Stock?
The current price of BridgeBio Pharma, Inc. - Common Stock is 48.88
When was BridgeBio Pharma, Inc. - Common Stock last traded?
The last trade of BridgeBio Pharma, Inc. - Common Stock was at 08/20/25 04:15 PM ET
What is the market capitalization of BridgeBio Pharma, Inc. - Common Stock?
The market capitalization of BridgeBio Pharma, Inc. - Common Stock is 7.85B
How many shares of BridgeBio Pharma, Inc. - Common Stock are outstanding?
BridgeBio Pharma, Inc. - Common Stock has 8B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.